GlassScriptPhysician profile
John Deis
NPI 1932632775
$3,515.36
in general payments reported to CMS, 2019-2025
26 companies · $1,756 in 2025
The $1,756 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.15 · 2022: $201 · 2023: $379 · 2024: $1,159 · 2025: $1,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,102 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,101.88 |
| Education | $192.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $838.30 | 2022-2025 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $479.40 | 2023-2025 | Ilumya, Odomzo, Blu-U |
| Ucb, INC. | $260.31 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $252.43 | 2023-2025 | Tremfya, Simponi Aria, Stelara |
| Lilly USA, LLC | $243.91 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $237.60 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $212.01 | 2023-2025 | Dupixent, Libtayo |
| Pfizer INC. | $147.51 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $134.73 | 2023-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $95.18 | 2024-2025 | Zoryve |
| Incyte Corporation | $94.08 | 2023-2025 | Opzelura |
| Dermavant Sciences, INC. | $84.44 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $73.23 | 2024-2025 | Nemluvio |
| Genzyme Corporation | $65.83 | 2025 | |
| Verrica Pharmaceuticals INC. | $49.99 | 2023-2024 | Ycanth |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $37.50 | 2023-2024 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.19 | 2024 | Spevigo |
| Organon LLC | $26.55 | 2025 | Vtama |
| Krystal Biotech INC | $22.55 | 2024 | Vyjuvek |
| Organogenesis INC. | $20.24 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.36 | 2025 | Cabtreo |
| Genentech USA, INC. | $19.15 | 2019 | |
| Convatec INC. | $18.73 | 2025 | |
| Amgen INC. | $18.72 | 2023 | Otezla |
| Kyowa Kirin, INC. | $18.25 | 2024 | Poteligeo |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Deis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.